Former Sanofi I&I exec Frédéric Marrache launches Bionyra with $165M to chase TL1A targets in IBD and eczema.

The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.

Former Sanofi I&I exec Frédéric Marrache launches Bionyra with $165M to chase TL1A targets in IBD and eczema.